Fig. 2.

Proportion of patients achieving at least a 50% improvement in PASI at week 2 (PASI 50), or at least a 75% or 90%, or a 100% improvement (PASI 75, PASI 90, PASI 100, respectively) at week 12 by: a age; < 65 years n = 581, ≥ 65 years n = 31; b sex; female n = 172, male n = 440; c body weight; < 60 kg n = 135, 60– < 80 kg n = 292, ≥ 80 kg n = 185; d biologic treatment history; experienced n = 61, naïve n = 551; e baseline PASI score; < 10 n  = 149, ≥ 10 n = 454. f Number of ixekizumab injections (80 mg) after baseline; 1, n = 151; 2–4, n = 327; 5–7 n = 105. PASI Psoriasis Area and Severity Index